ALAdrien Lam

Adrien Lam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Adrien Lam has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparing Gas and Inhaled Pharmacologic Interventions During Ex Vivo Lung Perfusion: A Systematic Review

    by Maira Machhiwala, Ryaan El-Andari, Parham Hassanzadeh, Adrien Lam, Daniel Gutierrez, Darren H. Freed, Jayan Nagendran

    Background.: Ex vivo lung perfusion (EVLP) has expanded the use of donor lungs by enabling ex vivo assessment, preservation, and rehabilitation before transplantation. Despite these advances, ischemia-reperfusion injury, inflammatory activation, pulmonary edema, and impaired lung mechanics continue to compromise graft quality and contribute to primary graft dysfunction. Inhaled and gaseous interventions have emerged as potential adjunctive therapies to improve donor lung preservation during EVLP; however, a standardized protocol has not yet been established. Methods.: PubMed and Embase were used to search human and animal studies evaluating inhaled and gaseous interventions administered during and after EVLP. Articles published from the database’s inception to September 22, 2025, were analyzed. Results.: Among the interventions examined, 10% carbon dioxide, carbon monoxide (CO), 40% oxygen (O 2 ), hydrogen, 40 ppm nitric oxide (NO) with 60% O 2 , 2% sevoflurane with 40%–50% O 2 , 2-S-amino-6-boronohexanoic acid, fasudil, and β 2 -adrenoreceptor agonists most effectively improved lung function. Interestingly, improvements from hydrogen and CO were observed after transplantation, rather than during EVLP, suggesting more persistent or delayed protective effects. Further optimized parameters were observed when moderate O 2 concentrations (40%–60%) were combined with either CO, NO, or sevoflurane, compared with O 2 alone. In contrast, argon, xenon, N-acetylcysteine, sevoflurane or NO with 6% O 2 , and liquid ventilation demonstrated minimal benefit. Conclusions.: Inhaled interventions can attenuate both mechanical damage and inflammatory pathways, particularly when used in tailored combinations with 40%–60% O 2 . Future research should prioritize standardizing protocols, optimizing gas composition and timing, and assessing long-term posttransplant outcomes to translate these findings into clinical practice.

  • Open Access

    Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens

    by David Yao, Raj S. Patel, Adrien Lam, Quarshie Glover, Cindy Srinivasan, Alex Herchen, Bruce Ritchie, Babita Agrawal

    There is a need to investigate novel strategies in order to create an effective, broadly protective vaccine for current and future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks. The currently available vaccines demonstrate compromised efficacy against emerging SARS-CoV-2 variants of concern (VOCs), short-lived immunity, and susceptibility to immune imprinting due to frequent boosting practices. In this study, we examined the specificity of cross-reactive IgG antibody responses in mRNA-vaccinated, AstraZeneca-vaccinated, and unvaccinated donors to identify potentially conserved, cross-reactive epitopes to target in order to create a broadly protective SARS-CoV-2 vaccine. Our study provides evidence for cross-reactive IgG antibodies specific to eight different spike (S) variants. Furthermore, the specificities of these cross-variant IgG antibody titers were associated to some extent with spike S1- and S2-subunit-derived epitopes P1 and P2, respectively. In addition, nucleocapsid (N)- and membrane (M)-specific IgG antibody titers correlated with N- and M-derived epitopes conserved across beta-CoVs, P3–7. This study reveals conserved epitopes of viral antigens, targeted by natural and/or vaccine-induced human immunity, for future designs of next-generation COVID-19 vaccines.